We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+12.52%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$270M
AUM Growth
+$34.2M
Cap. Flow
+$5.84M
Cap. Flow %
2.17%
Top 10 Hldgs %
97.39%
Holding
22
New
3
Increased
–
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$5.03M
2
CSBR icon
Champions Oncology
CSBR
+$478K

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$559K
2
LSTA icon
Lisata Therapeutics
LSTA
+$544K
3
CRBP icon
Corbus Pharmaceuticals
CRBP
+$316K

Sector Composition

Rank Sector Weight
1 Healthcare 20.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$213M 78.82%
4,397,838
– –
AMPE
2
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$11.9M 4.4%
11,294
– –
TOVX icon
3
Theriva Biologics
TOVX
$10.2M
$8.55M 3.17%
427
– –
ARCT icon
4
Arcturus Therapeutics
ARCT
$157M
$7M 2.6%
159,331
– –
CEMP
5
DELISTED
Cempra, Inc.
CEMP
$5.63M 2.09%
+180,800
New +$5.03M
ABEO icon
6
Abeona Therapeutics
ABEO
$345M
$4.57M 1.69%
54,391
– –
CRBP icon
7
Corbus Pharmaceuticals
CRBP
$170M
$4.23M 1.57%
85,464
-6,203
-7% -$316K
LUMO
8
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.73M 1.38%
11,382
– –
ADXS
9
DELISTED
Advaxis Inc
ADXS
$2.77M 1.03%
18,333
– –
ENLV icon
10
Enlivex Ltd
ENLV
$70.7M
$1.31M 0.49%
564
– –
NBSE
11
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.26M 0.47%
513
– –
KERX
12
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.01M 0.37%
200,000
– –
ALDX icon
13
Aldeyra Therapeutics
ALDX
$91.7M
$921K 0.34%
135,800
– –
ADXSW
14
DELISTED
Advaxis Inc Warrants
ADXSW
$798K 0.3%
112,500
– –
LSTA icon
15
Lisata Therapeutics
LSTA
$15.2M
$600K 0.22%
3,705
-2,962
-44% -$544K
GLMD icon
16
Galmed Pharmaceuticals
GLMD
$3.94M
$495K 0.18%
361
– –
CSBR icon
17
Champions Oncology
CSBR
$85.1M
$397K 0.15%
+111,111
New +$478K
EVOK
18
DELISTED
Evoke Pharma
EVOK
$184K 0.07%
387
– –
ZSAN
19
DELISTED
Zosano Pharma Corporation
ZSAN
$42K 0.02%
27
– –
APTO
20
DELISTED
Aptose Biosciences, Inc.
APTO
$31K 0.01%
27
– –
IOVA icon
21
Iovance Biotherapeutics
IOVA
$2.23B
– –
-97,100
Closed -$559K

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Knoll Capital Management held 22 positions worth $270M, up 15% from $236M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Knoll Capital Management's Q4 2015 filing shows 3 new, 2 reduced and 1 closed positions. Its largest new stake was Cempra, Inc.: 180,800 shares worth $5.63M. The largest sale was Iovance Biotherapeutics, an estimated $559K.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 20% a quarter earlier.

  • Knoll Capital Management's largest Q4 2015 buy was Cempra, Inc.: 180,800 shares worth $5.63M.
  • Knoll Capital Management's biggest Q4 2015 reduction was Lisata Therapeutics, cutting an estimated $544K.
  • Knoll Capital Management fully exited Iovance Biotherapeutics in Q4 2015, selling an estimated $559K.
  • Knoll Capital Management's ten largest holdings make up 97% of its $270M portfolio in Q4 2015.
  • Knoll Capital Management opened 3 new positions and closed 1 in Q4 2015.
  • Knoll Capital Management's portfolio value rose 15% quarter-over-quarter to $270M.

Based on Knoll Capital Management's 13F filing for Q4 2015, filed 17 Feb 2016.